Spontaneous parkinsonism is associated with cognitive impairment in antipsychotic-naive patients with first-episode psychosis: A 6-month follow-up study

Schizophrenia Bulletin

Volumn 40, Issue 5, 2014, Pages 1164-1173

  Cuesta, Manuel J ^a   Sánchez Torres, Ana M ^a   De Jalón, Elena García ^a   Campos, Maria S ^a   Ibáñez, Berta ^b   Moreno Izco, Lucía ^a   Peralta, Víctor ^a  

^a Instituto de Investigación Sanitaria de Navarra   (Spain)

^b Fundacion Miguel Servet   (Spain)

Author keywords

Abnormal movements; Cognition; Extrapyramidal signs; Neuropsychological impairment; Schizophrenia

Indexed keywords

BENZATROPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; OLANZAPINE; RISPERIDONE;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; AKATHISIA; ARTICLE; ATTENTION; BARNES AKATHISIA SCALE; CATATONIA; CLINICAL EXAMINATION; COGNITIVE DEFECT; CONTROLLED STUDY; DYSKINESIA; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; HUMAN; HYPOKINESIA; INTELLIGENCE QUOTIENT; LONGITUDINAL STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEMORY; MODIFIED ROGERS SCALE; MOTONEURON; MUSCLE RIGIDITY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROLOGIC EXAMINATION; NEUROLOGICAL EVALUATION SCALE; PARKINSONISM; PREDICTIVE VALUE; PRIORITY JOURNAL; PSYCHOSIS; RESPONSE TIME; SALIVATION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIMPSON-ANGUS SCALE; SPONTANEOUS PARKINSONISM; TREMOR; WECHSLER MEMORY SCALE; COGNITION DISORDERS; COMORBIDITY; MIDDLE AGED; PARKINSONIAN DISORDERS; PSYCHOTIC DISORDERS;

ADULT; COGNITION DISORDERS; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PARKINSONIAN DISORDERS; PSYCHOTIC DISORDERS;

EID: 84907368345     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbt125     Document Type: Article

References (55)

1. Kahlbaum K. Catatonia. Baltimore: John Hopkins University Press; 1874/1973.
2. Kraepelin E. Dementia Praecox and Paraphrenia. Chicago, IL: Chicago Medical Book Company; 1896/1919.
3. Bleuler E. Dementia Praecox. New York, NY: International Universitity Press; 1911/1950.
4. Rogers D. The motor disorders of severe psychiatric illness: a conflict of paradigms. Br J Psychiatry. 1985;147: 221-232.
5. Friedman JH. Historical perspective on movement disorders. J Clin Psychiatry. 2004;65(suppl 9): 3-8.
6. Docx L, Morrens M, Bervoets C, et al. Parsing the components of the psychomotor syndrome in schizophrenia. Acta Psychiatr Scand. 2012;126: 256-265.
7. Walther S, Strik W. Motor symptoms and schizophrenia. Neuropsychobiology. 2012;66: 77-92.
8. Peralta V, Campos MS, De Jalón EG, Cuesta MJ. Motor behavior abnormalities in drug-naïve patients with schizophrenia spectrum disorders. Mov Disord. 2010;25: 1068-1076.
9. Wolff AL, O'Driscoll GA. Motor deficits and schizophrenia: the evidence from neuroleptic-naïve patients and populations at risk. J Psychiatry Neurosci. 1999;24: 304-314.
10. Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry. 2000;61(suppl 4): 10-14.
11. Torrey EF. Studies of individuals with schizophrenia never treated with antipsychotic medications: a review. Schizophr Res. 2002;58: 101-115.
12. McCreadie RG, Padmavati R, Thara R, Srinivasan TN. Spontaneous dyskinesia and parkinsonism in never-medicated, chronically ill patients with schizophrenia: 18-month follow-up. Br J Psychiatry. 2002;181: 135-137.
13. Pappa S, Dazzan P. Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review. Psychol Med. 2009;39: 1065-1076.
14. Cuesta MJ, Peralta V, Zarzuela A, Calvo R, García M, Serrano F. Neurological soft-signs in psychosis: threshold criteria for discriminating normal controls and for predicting cognitive impairment. Schizophr Res. 2002;58: 263-271.
15. Bombin I, Arango C, Buchanan RW. Significance and meaning of neurological signs in schizophrenia: two decades later. Schizophr Bull. 2005;31: 962-977.
16. Northoff G, Nagel D, Danos P, Leschinger A, Lerche J, Bogerts B. Impairment in visual-spatial function in catatonia: a neuropsychological investigation. Schizophr Res. 1999;37: 133-147.
17. APA. DSM-IV-TR. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
18. Cuesta MJ, Jalón EG, Campos MS, Peralta V. Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis. Br J Psychiatry. 2009;194: 439-445.
19. Andreasen NC, Flaum M, Arndt S. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry. 1992;49: 615-623.
20. Perkins DO, Leserman J, Jarskog LF, Graham K, Kazmer J, Lieberman JA. Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory. Schizophr Res. 2000;44: 1-10.
21. Cuesta MJ, García de Jalón E, Campos MS, Ibáñez B, Sánchez-Torres AM, Peralta V. Duration of untreated negative and positive symptoms of psychosis and cognitive impairment in first episode psychosis. Schizophr Res. 2012;141: 222-227.
22. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212: 11-19.
23. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154: 672-676.
24. Guy W. Abnormal Involuntary Movement Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health Education and Welfare; 1976.
25. Lund CE, Mortimer AM, Rogers D, McKenna PJ. Motor, volitional and behavioural disorders in schizophrenia. 1: assessment using the Modified Rogers Scale. Br J Psychiatry. 1991;158: 323-327, 333-326.
26. Buchanan RW, Heinrichs DW. The Neurological Evaluation Scale (NES): a structured instrument for the assessment of neurological signs in schizophrenia. Psychiatry Res. 1989;27: 335-350.
27. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39: 486-487.
28. Peluso MJ, Lewis SW, Barnes TR, Jones PB. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br J Psychiatry. 2012;200: 387-392.
29. Caroff SN, Mann SC, Campbell EC, Sullivan KA. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry. 2002;63(suppl 4): 12-19.
30. Miller DD, Caroff SN, Davis SM, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry. 2008;193: 279-288.
31. Brown L, Sherbenou R, Johnsen S. TONI-2. Test de Inteligencia No Verbal. Madrid: TEA Ediciones; 1995.
32. Gurpegui M, Alvarez E, Bousoño M, Ciudad A, Carlos Gómez J, Olivares JM. Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year followup of schizophrenia outpatients with prominent negative symptoms. Eur Neuropsychopharmacol. 2007;17: 725-734.
33. Peralta V, Cuesta MJ. Neuromotor abnormalities in neuroleptic- naive psychotic patients: antecedents, clinical correlates, and prediction of treatment response. Compr Psychiatry. 2011;52: 139-145.
34. Owens DG. Involuntary disorders of movement in chronic schizophrenia-The role of the illness and its treatment. Psychopharmacology Suppl. 1985;2: 79-87.
35. Caligiuri MP, Lohr JB, Jeste DV. Parkinsonism in neuroleptic- naive schizophrenic patients. Am J Psychiatry. 1993;150: 1343-1348.
36. Chatterjee A, Chakos M, Koreen A, et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry. 1995;152: 1724-1729.
37. Loonen AJ, van Praag HM. Measuring movement disorders in antipsychotic drug trials: the need to define a new standard. J Clin Psychopharmacol. 2007;27: 423-430.
38. Janno S, Holi MM, Tuisku K, Wahlbeck K. Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population. BMC Neurol. 2005;5: 5.
39. Calvo-Gómez JM, Sánchez-Pedraza R, Jaramillo- González LE, Tarcisio-Mantilla C. Validating the Simpson-Angus Extrapyramidal Collateral Symptom Evaluation Scale. Rev Salud Publica (Bogota). 2006;8: 74-87.
40. Peralta V, Cuesta MJ, Martinez-Larrea A, Serrano JF. Differentiating primary from secondary negative symptoms in schizophrenia: a study of neuroleptic-naive patients before and after treatment. Am J Psychiatry. 2000;157: 1461-1466.
41. Rodriguez-Oroz MC, Jahanshahi M, Krack P, et al. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol. 2009;8: 1128-1139.
42. Honer WG, Kopala LC, Rabinowitz J. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness. J Psychopharmacol. 2005;19: 277-285.
43. Barch DM, Ceaser A. Cognition in schizophrenia: core psychological and neural mechanisms. Trends Cogn Sci. 2012;16: 27-34.
44. Peralta V, Cuesta MJ. The effect of antipsychotic medication on neuromotor abnormalities in neuroleptic-naive nonaffective psychotic patients: a naturalistic study with haloperidol, risperidone, or olanzapine. Prim Care Companion J Clin Psychiatry. 2010;12. doi: 10.4088/PCC.09m00799gry.
45. Chong SA, Subramaniam M, Verma S. Spontaneous parkinsonism in antipsychotic-naive patients with first-episode psychosis. Can J Psychiatry. 2005;50: 429-431.
46. Smith MJ, Barch DM, Csernansky JG. Bridging the gap between schizophrenia and psychotic mood disorders: relating neurocognitive deficits to psychopathology. Schizophr Res. 2009;107: 69-75.
47. Reichenberg A, Harvey PD, Bowie CR, et al. Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophr Bull. 2009;35: 1022-1029.
48. Peralta V, Basterra V, Campos MS, de Jalón EG, Moreno-Izco L, Cuesta MJ. Characterization of spontaneous parkinsonism in drug-naive patients with nonaffective psychotic disorders. Eur Arch Psychiatry Clin Neurosci. 2012;262: 131-138.
49. Strous RD, Alvir JM, Robinson D, et al. Premorbid functioning in schizophrenia: relation to baseline symptoms, treatment response, and medication side effects. Schizophr Bull. 2004;30: 265-278.
50. Obeso JA, Rodriguez-Oroz MC, Goetz CG, et al. Missing pieces in the Parkinson's disease puzzle. Nat Med. 2010;16: 653-661.
51. Robbins TW, Arnsten AF. The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annu Rev Neurosci. 2009;32: 267-287.
52. Keshavan MS, Nasrallah HA, Tandon R. Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse. Schizophr Res. 2011;127: 3-13.
53. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III-The final common pathway. Schizophr Bull. 2009;35: 549-562.
54. Domellöf ME, Elgh E, Forsgren L. The relation between cognition and motor dysfunction in drug-naive newly diagnosed patients with Parkinson's disease. Mov Disord. 2011;26: 2183-2189.
55. Goldberg TE, Keefe RS, Goldman RS, Robinson DG, Harvey PD. Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. Neuropsychopharmacology. 2010;35: 1053-1062.